Melanoma articles
Plain-language, evidence-graded explainers built from a curated research corpus. Each article cites peer-reviewed sources and points to specialist follow-up.
Tebentafusp (Kimmtrak) for uveal melanoma: the first therapy to improve survival
Uveal melanoma is a rare eye cancer with historically grim prognosis once it spreads. Tebentafusp (Kimmtrak), approved by the FDA in January 2022, is the first treatment ever shown in a Phase 3 trial to improve overall survival in metastatic uveal melanoma. This article explains what it is, who it is for, and what the evidence shows.
immunotherapyNivolumab + relatlimab (Opdualag) for advanced melanoma: what patients need to know
A plain-language guide to Opdualag — the dual LAG-3 + PD-1 checkpoint blockade approved in 2022 for first-line advanced melanoma. What the RELATIVITY-047 trial showed, who it is for, how it compares to other immunotherapy combinations, and what side effects to expect.
treatmentMelanoma treatment overview: what happens after diagnosis?
A plain-language guide for newly-diagnosed patients: how melanoma is staged, what the main treatment options are (surgery, immunotherapy, targeted therapy, TIL therapy), and what to expect at each step of the journey.